MGAM and cancer: In the end, our data provide a molecular basis to additional studies aimed at investigating the role of Glo1/PD-L1 as relevant biomarkers to predict treatment response and, possibly, to improve the clinical response rate of PD-L1/PD-1 blockade in aggressive mPCa, and maybe across other cancer types, where Glo1 is overexpressed to reduce MG-H1 levels.